This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Inamed Goes With Allergan

Inamed (IMDC) has agreed to be acquired by Allergan (AGN - Get Report), but one divestiture designed to make the deal more palatable to regulators could attract several bidders.

Botox-maker Allergan said Tuesday night that it had signed a definitive agreement to buy Inamed, a maker of breast implants and dermatology treatments. Allergan made its offer last month , topping an earlier $2.8 billion bid from Medicis (MRX) of Scottsdale, Ariz.

Once Medicis decided to drop out of the bidding, it withdrew its agreement to buy Inamed, Santa Barbara, Calif., and received a $90 million break-up fee.

The value of the Allergan offer, now estimated at $3.4 billion, keeps changing because the company is offering $84 in cash or 0.8498 shares for each share of Inamed. Initially, the stock swap also was worth $84 a share, but Allergan's stock has since moved up. On Wednesday, the exchange rate made it worth just above $90.

The companies agreed that 45% of the Inamed shares tendered will be exchanged for cash and 55% will be exchanged for Allergan shares. Allergan's exchange offer started last month and will continue through Jan. 9.

The deal must be approved by the Federal Trade Commission. "We continue to work with the appropriate regulatory authorities as they review the transaction, and do not anticipate that the regulatory process will lead to any material delay in the closing of the transaction," Nicholas L. Teti, Inamed's chairman and CEO of Inamed, said.

To improve its chances with the FTC, Inamed agreed to cancel its license to the experimental dermatology product Reloxin, which is similar to Botox. Assuming the Allergan-Inamed deal is approved, rights to Reloxin will revert back to its developer, the French drug company Ipsen Ltd. Ipsen will pay Inamed $10 million.

Since Ipsen licensed the Reloxin rights in mid-2002, Inamed has been developing the drug to compete with Botox in the U.S., Canada and Japan. Until the Allergan-Inamed deal is closed, Inamed will be responsible for late-stage clinical trials and preparing data that will be submitted to the Food and Drug Administration. Ipsen said Wednesday it expects to seek FDA approval for Reloxin in 2007.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
MRX $0.00 0.00%
IMDC $0.01 6.18%
AGN $272.34 2.27%
AAPL $94.99 -0.02%
FB $99.54 -0.21%


Chart of I:DJI
DOW 16,014.38 -12.67 -0.08%
S&P 500 1,852.21 -1.23 -0.07%
NASDAQ 4,268.7630 -14.99 -0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs